9 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 9 of 9 clinical reviews.
Wegovy (semaglutide 2.4 mg) is associated with falling ALT levels in most patients treated for obesity, driven by weight loss and liver fat reduction. This article separates what trial evidence establishes from what still needs verification, and covers monitoring, red flags, and when ALT changes need workup.
Semaglutide 2.4 mg (Wegovy) typically lowers AST by reducing hepatic fat. Learn the expected magnitude, time course, monitoring schedule, and when AST changes on Wegovy warrant clinical attention.
Wegovy (semaglutide 2.4 mg) changes body composition measurably on DEXA. Here is what happens to fat mass, lean mass, and visceral fat, plus when to scan and how to preserve muscle.
A guide to how Wegovy (semaglutide 2.4 mg) affects estimated glomerular filtration rate (eGFR), including trial data from STEP-1, FLOW, and SELECT, monitoring timelines, and what eGFR changes mean for patients on GLP-1 therapy.
Semaglutide 2.4 mg (Wegovy) changes multiple CMP markers, including fasting glucose, liver enzymes, kidney function, and electrolytes. Here is what the clinical trial data shows and when to recheck labs.
Wegovy (semaglutide 2.4 mg) improves multiple lipid panel markers. Learn the direction, magnitude, and timeline of cholesterol and triglyceride changes backed by STEP trial data.
Semaglutide 2.4 mg (Wegovy) consistently lowers fasting insulin and HOMA-IR in people with obesity. Learn the mechanism, magnitude, time course, and how to monitor fasting insulin on Wegovy.
Wegovy (semaglutide 2.4 mg) has been reported to lower fasting triglycerides in its clinical trial program. Here is what is established, what is plausible but unconfirmed at this draft stage, and how to think about monitoring.
Semaglutide 2.4 mg (Wegovy) significantly reduces visceral adipose tissue in clinical trials. Learn the magnitude, timeline, mechanism, and monitoring approach backed by RCT evidence.